Full Text View
Tabular View
Study Results
Related Studies
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
This study has been completed.
Study NCT00561951   Information provided by Pfizer

First Received on November 19, 2007.   Last Updated on July 11, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Overactive Bladder
Additional conditions recognized in this trial
Urinary Bladder, Overactive
More general conditions related to this trial
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
fesoterodine fumarate
Placebo
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services